Amoxicillin good for

All the randomized patients who received at least 1 dose of the study medication were evaluated in the safety analysis.

Safety evaluations were carried out throughout the whole study period (from visit 1 to visit 4). They came from 5 participating Latin American countries.

Of these 70 (83.3%) could be evaluated for efficacy and safety at the end of the treatment (visit 3); 34 of the group treated with moxifloxacin and 36 of the group treated with amoxicillin.

A total of 37 patients (52.8%) were hospitalized; 17 in the moxifloxacin group and 20 in the amoxicillin group.

The characteristics of the patients are given in Table 1. Causal organisms were cultured pretreatment in 36 of the 70 patients evaluated (51.4%); 19 in the group treated with moxifloxacin, and 17 in the group treated with amoxicillin.

Gram-positive pathogens were cultured in samples from 29 patients (80.5%). S pneumoniae was detected in the samples of 28 patients (77.7%). Gram-negative pathogens were cultured in samples from 7 patients (19.4%), the most commonly isolated pathogen being H influenzae in 3 patients (8.3%). No pathogens were isolated in blood cultures (Table 2). The serological determinations were positive for atypical microorganisms in 18 of the 70 patients evaluated (25%), mainly M pneumoniae (n=11). This was defined as the presence of a positive serology for atypical microorganisms and pretreatment isolation of a causal agent in a positive culture.

With respect to pneumococcal etiology, 28 of the 70 patients evaluated (40%) had proven pneumococcal pneumonia, demonstrated by positive sputum culture in 27 patients and by isolation in BAL in 1 case.

The susceptibility to penicillin of these 28 strains of S pneumoniae was tested.

With the breakpoints traditionally used to ascertain susceptibility to penicillin, 10 strains (35.7%) were shown to be susceptible to penicillin (MIC 1 µg/mL) and 16 (57.1%), intermediate resistance (MIC between 0.1 and 1 µg/mL) (Tables 3 and 4). However, no strain of S pneumoniae presented resistance to penicillin as defined by the new criteria of the National Committee for Clinical Laboratory Standards (NCCLS) (MIC>4 µg/mL).

15 The initial bacteriological findings were comparable in the 2 treatment groups. With respect to macrolides, 4 strains (14.3%) had an MIC>2 µg/mL for clarithromycin and 1 of them an MIC>8 µg/mL. No differences were observed between the hospitalized patients and the outpatients in the percentage of strains with decreased susceptibility to antibiotics. The clinical success rate in the EP at visit 3 (end of treatment) was 94.1% for moxifloxacin and 91.7% for amoxicillin, and at visit 4 (the follow-up visit) this figure was 91.2% for moxifloxacin and 85.7% for amoxicillin. In the ITT population the clinical success rate at visit 3 was 91.9% of the patients treated with moxifloxacin and 85.4% of those treated with amoxicillin, and at the follow-up visit, 89.2% for moxifloxacin and 84.2% for amoxicillin (Table 5).

In the EP, 2 of the 34 patients in the group treated with moxifloxacin (5.9%) and 3 of the 36 patients in the group treated with amoxicillin (8.3%) were considered clinical failures at the end-of-treatment visit (visit 3). In the 2 treated with moxifloxacin no pathogen was isolated; however in the 3 treated with amoxicillin, pathogens were isolated ( S epidermis [n=1] and H influenzae [n=1]).

The bacteriological success rate in the EP at amoxicillin for babies cough the end of treatment and on follow up (visit 4) was 86.6% in the group treated with moxifloxacin and 84.6% in t he group treated with amoxicillin.

The bacteriological success rate at the end of treatment (visit 3) was 88.2% for moxifloxacin and 87.5% for amoxicillin (Table 6). Bacteriological failure (persistence, presumed persistence, or persistence with superinfection) at the end of treatment and after follow up occurred in 11.8% and 13.3% respectively, in the group treated with moxifloxacin and in 12.5% and 15.3% respectively in the group treated with amoxicillin.

The sample size in the Latin American arm of the study does not have sufficient statistical power to allow for comparisons of efficacy between the 2 treatment groups. The comparison for the study as a whole has been described recently.

The pretreatment MIC values for S pneumoniae ranged between 0.032 and 0.75 mg/L for moxifloxacin and from 0.016 to 1.5 mg/L for amoxicillin.

In the cases of H influenzae they ranged from 0.032 to 0.25 mg/L for moxifloxacin and from 0.125 to 12 mg/L for amoxicillin.

During treatment adverse events considered by the investigator to be related (possibly or probably) to the study medication occurred in 27 of the 39 patients (69.2%) in the group treated with moxifloxacin and in 20 of the 45 patients (44.4%) in the group treated with amoxicillin. The most frequently recorded adverse events were gastrointestinal disturbances (nausea, vomiting and diarrhea) in the group treated with moxifloxacin and liver function test abnormalities in the amoxicillin group.

Drug-related adverse events in both treatment groups were mainly mild to moderate in intensity and were subsequently resolved. Severe drug-related adverse events were observed in 2 patients in the group treated with amoxicillin (pulmonary embolism and pneumonia relapse) and in 1 patient in the group treated with moxifloxacin (myocardial ischemia with ventricular fibrillation). Twelve patients discontinued the study medication owing to an adverse event, 4 in the group treated with moxifloxacin and 8 in the group treated with amoxicillin.

Two patients, 1 from each group, died during the study. Neither of these deaths was considered to be related to the study drug treatment.

The results of this study reveal a high prevalence of S pneumoniae with reduced susceptibility to penicillin in patients with CAP in Latin America. Moreover, 8.6% of the patients presented mixed infection.

These results are relevant to the orientation of empirical treatment of CAP in Latin America. One of the main reasons why the treatment of CAP continues to be a challenge for doctors is the large number of causal organisms and the changing patterns of their susceptibility to different antibiotics.

Antibiotic treatment for CAP should be active against the most commonly isolated pathogens and, above all, against S pneumoniae .

A growing problem recently has been the appearance of strains of S pneumoniae whose resistance to penicillin is not mediated by beta-lactamase. This resistance of the pneumococcus to penicillin is a worldwide problem that has been increasing in recent years to different degrees in different geographical areas. The highest levels of resistance in Europe have been identified in countries where they account for 50% of the isolations: France, Hungary, Spain, Portugal, and Iceland. 16-­25 In the USA, the level of resistant strains went from 3% in 1988 to 32% in 1998.

26 In Latin America, penicillin resistance is estimated to be around 25%, although this is mainly intermediate resistance, with an MIC between 0.12 and 1 µg/mL. Our results confirm these high levels of penicillin resistance. Of the 28 strains of pneumococcus isolated, 10 (35.7%) were shown to be susceptible to penicillin, and 18 (64.3%) resistant; 2 strains (7.1%) evidenced high resistance to penicillin and 16 (57.1%) intermediate resistance. It should be noted that this in vitro resistance does not correspond directly with clinical response, 27 so that the NCCLS changed the breakpoints for susceptibility to penicillin to 4 µg/mL in 2002.

15 None of the pneumococcus isolated in this study had an MIC of >4 µg/mL.

Penicillin resistance also occasionally implies cross-resistance with other antibiotics, such as macrolides, sulfamides, and cephalosporins, so that the activity of the new macrolides, such as clarithromycin or azithromycin, against the pneumococcus is often weaker against the penicillin resistant strains.

The increase in the patterns of resistance of most of the organisms that cause CAP makes it necessary to search for new antimicrobial agents that can be administered empirically. The number of available therapeutic options has increased thanks to the recent development of the fluoroquinolones, whose activity against S pneumoniae is not affected by resistance to penicillin or macrolides.

28,29 The new fluoroquinolones with action against the pneumococcus maintain their activity against S pneumoniae , even against strains highly resistant to penicillin.

Within this group moxifloxacin is the drug that presents the greatest activity in vitro against the pneumoccus. Most etiology studies show that S pneumoniae continues to be the main cause of CAP. The incidence of other pathogens varies geographically and according to the season. 3,30-­34 The other causal agents in order of frequency are L pneumophila , 31 Klebsiella pneumoniae 32 and H influenzae .

32 Occasionally viral agents and C pneumoniae have been isolated with greater frequency than S pneumoniae , especially in the individuals treated as outpatients. Few studies have been conducted to study the etiology of CAP in Latin America.

In a study carried out in Brazil it was observed that "atypical agents," including Chlamydia sp, either alone or in mixed infections can be detected in around 50% of cases when serological techniques are used.

It should be remembered that the diagnostic tests have limitations, such that the etiology is unknown in 30% to 50% of CAP patients, although some studies show that most cases in which no etiological diagnosis is reached are due to S pneumoniae . The number of patients with microbiologically valid specimens for our study was 36/84 (42.8%).

The pathogens most frequently detected were S pneumoniae (78%), followed in frequency by H influenzae (8.3%) and by M pneumoniae in third place.

The role of the "atypical" pathogens is very controversial, given that their frequency as causal agents of CAP depends on the diagnostic tests and criteria used.

The term "atypical" is falling into disuse because the clinical syndrome caused by these microorganisms is not distinctive, but it can still be used to refer to a group of microorganisms ( M pneumoniae , C pneumoniae and Legionella spp) rather than to a clinical picture. What is more important is that these are in many cases intracellular organisms, a characteristic that limits the activity of some antimicrobial agents, such as the beta-lactams, and the possibility of their causing mixed infection with classical bacteria with a frequency that ranges between 10% and 40% of cases according to studies undertaken.

31,38,39 It is difficult to estimate how important these atypical pathogens are, and whether they require specific treatment. However, various studies have shown that in both hospitalized patients and outpatients the clinical course is less complicated when macrolides are used as part of the therapeutic regimen or when a quinolone is used alone. The serological determinations were positive for atypical microorganisms in 25% of the EP, above all M pneumoniae and L pneumophila . Mixed infections were found in 6 patients (8.5%), (defined as the presence of positive serology for atypical microorganisms and the isolation by positive pretreatment culture of a causal agent.

Studies designed to investigate the etiology of CAP and its resistance patterns are essential for the orientation of empirical therapy. The new quinolones, such as moxifloxacin, have been shown to be at least as effective as the reference antibiotics in the treatment of CAP. *The names of the other members of the CAP 5 Latin American Study Group are shown in the appendix.

The members of the CAP 5 Latin American study group are as follows: Abel Jasovich (Argentina); Jose R.

Jardim (Brazil), Marcelo Wolff (Chile), Jose Alva, Ariel Estrada, Mayra Loera, Juan Morales, Gerardo Rico, Enrique Obispo, and Juan Urueta (Mexico), and Homero Bagnulo (Uruguay).

Servicio de Neumologia (UVIR, escalera 2, planta 3).

Please note that Internet Explorer version 8.x is not supported as of January 1, 2016.

Please refer to this support page for

more

Objective: Our goal was to compare the efficacy of azithromycin with that of amoxicillin for the treatment of Chlamydia trachomatis infection during pregnancy.

Study Design: A randomized controlled trial of pregnant women with cervical C trachomatis infection receiving care at two inner-city, university-based prenatal clinics. Pregnant women were randomly assigned to receive either oral amoxicillin, 500 mg, three times daily for 7 days, or oral azithromycin, 1 g, in a single dose.

Tests of cure were scheduled 4 weeks after initiation of treatment. Statistical analysis was performed by using the Student t test and ? 2 analysis. Results: One hundred twenty-nine pregnant women were enrolled, and 110 (85%) completed the protocol.

There was similar treatment efficacy between amoxicillin and azithromycin (58% vs 64%, respectively, P = .56). In the amoxicillin group 3 women (5.5%) were intolerant, compared with 6 (10.9%) in the azithromycin group ( P = .31). Conclusion: Amoxicillin and azithromycin are equally efficacious in the treatment of cervical C trachomatis during pregnancy. (Am J Obstet Gynecol 2001;184:1352-6.) Previous article in issue Next article in issue. Reprint requests: Gavin Jacobson, MD, UWMS-MCC, Sinai Samaritan Medical Center, 950 N 12th St, Milwaukee, WI 53233. About ScienceDirect Remote access Shopping cart Advertise Contact and support Terms and conditions Privacy policy.

We use cookies to help provide and enhance our service and tailor content and ads.

Amoxicillin, or BRL-2333, is a penicillin G derivative first described in the literature in 1972.

6 Amoxicillin has similar activity to penicillin and ampicillin, but leads to higher serum concentrations than ampicillin. Amoxicillin was granted FDA approval on 18 January 1974. Type Small Molecule Groups Approved, Vet approved Structure.

Amoxicillin alone is indicated to treat susceptible bacterial infections of the ear, nose, throat, genitourinary tract, skin, skin structure, and lower respiratory tract. 17,18 Amoxicillin is given with calvulanic acid to treat acute bacterial sinusitis, community acquired pneumonia, lower respiratory tract infections, acute bacterial otitis media, skin and skin structure infections, and urinary tract infections.